On December 18, Novonesis announced that the first of its five commercialized HMOs has been approved in China. With the approval of 2′-FL (2′-fucosyllactose) as a food nutrient enhancer, infant formula manufacturers in China can now apply to the National Market Supervision Administration for approval of products containing the company’s 2′-FL. The approval applications for the other HMO products in Novonesis’s portfolio have also been formally submitted. (Source: Novonesis Human Health)
Sign Up to Receive China Updates Weekly Newsletter for FREE, HERE
Visit HPA-China’s Information Hub, HERE